Estradiol/levonorgestrel sequential transdermal - Merck KGaA

Drug Profile

Estradiol/levonorgestrel sequential transdermal - Merck KGaA

Alternative Names: EMD-59265; Fem7 Combi

Latest Information Update: 09 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnanes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 31 Dec 2002 Fem7® Combi has been licensed to Gedeon Richter in many Central European, Eastern European and Commonwealth of Independent States countries
  • 27 May 2002 A study has been added to the adverse events and Women's Health therapeutic trials sections
  • 15 Nov 2001 Launched for Menopausal syndrome in France (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top